+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of atrial natriuretic peptide and nitroprusside on isolated pulmonary resistance and conduit arteries from rats with pulmonary hypertension

Effects of atrial natriuretic peptide and nitroprusside on isolated pulmonary resistance and conduit arteries from rats with pulmonary hypertension

British Journal Of Pharmacology. 110(4): 1363-1368

1. The relaxant effects of atrial natriuretic peptide (ANP) and nitroprusside were studied on prostaglandin F-2alpha (PGF-2alpha)-contracted preparations of pulmonary resistance vessels (internal diameter 200-500 mu-m) and main pulmonary arteries taken from rats with pulmonary hypertension induced by monocrotaline (105 mg kg-1, s.c., 4 weeks previously). Control rats received saline. 2. In preparations from monocrotaline-treated rats, the potencies (negative log EC-50) of ANP on resistance vessels (8.45) and main pulmonary arteries (8.25) were similar to those obtained in vessels from control rats (8.78 and 8.53 respectively), whereas those of nitroprusside were significantly less than in controls in both resistance vessels (7.13 compared with 7.63 in controls; three fold decrease in potency) and main pulmonary arteries (6.92 compared with 8.17 in controls; 18 fold decrease in potency). 3. On pulmonary resistance vessels from monocrotaline-treated rats, the maximum relaxant responses to ANP and nitroprusside, and also to pinacidil, were increased compared with controls, and reversal of the PGF-2alpha-induced contraction by these drugs was greater than 100%. In contrast, on main pulmonary arteries from monocrotaline-treated rats, the maximum relaxations to ANP and nitroprusside were not increased relative to controls, and reversal of PGF-2alpha was not greater than 100%. 4. Since the high potency of ANP on pulmonary resistance and conduit arteries is retained in vessels from rats with pulmonary hypertension, whether induced by monocrotaline (this study) or by chronic hypoxia (previous findings), it is postulated that elevation of plasma levels of ANP by use of drugs that inhibit the breakdown of this endogenous peptide, may be one approach to the pharmacological treatment of pulmonary hypertension.

(PDF emailed within 0-6 h: $19.90)

Accession: 008559886

Download citation: RISBibTeXText

PMID: 8306077

DOI: 10.1111/j.1476-5381.1993.tb13970.x

Related references

The relaxant effects of atrial natriuretic peptide and nitroprusside on pulmonary arteries from rats with monocrotaline induced pulmonary hypertension. British Journal of Pharmacology 104(PROC SUPPL OCT): 112P, 1991

Inhibition of hypoxic pulmonary vasoconstriction in isolated rat resistance arteries by atrial natriuretic peptide. European Respiratory Journal 10(9): 2061-2065, 1997

Developmental differences in atrial natriuretic peptide mediated relaxation of pulmonary arteries isolated from juvenile lambs with congenital heart disease and high pulmonary blood flow. Pediatric Research 49(4 Part 2): 37A, 2001

Pulmonary vasodilatory action of endogenous atrial natriuretic factor in rats with hypoxic pulmonary hypertension. Effects of monoclonal atrial natriuretic factor antibody. Circulation Research 70(1): 184-192, 1992

Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia-induced pulmonary hypertension in rats. Virchows Archiv 439(6): 808-817, 2001

Effects of high pulmonary venous pressure and atrial natriuretic peptide on pulmonary vascular resistance and pulmonary vascular incremental resistance. Japanese Circulation Journal 55(SUPPL A): 333, 1991

Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clinical Science 81(3): 379-385, 1991

Vasodilator responses to alpha-human-atrial natriuretic peptide in isolated omental and pulmonary arteries from rabbit and man. Acta Physiologica Scandinavica 134(3): 391-397, 1988

Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. American Heart Journal 136(2): 297-301, 1998

Atrial natriuretic peptide prevents hypoxia induced pulmonary hypertension rats. Brenner, B M And J H Laragh (Ed ) American Society Of Hypertension Symposium Series, Vol 3 Progress in Atrial Peptide Research; Third World Congress, New York, New York, Usa, May 1988 Xxxi+683p Raven Press: New York, New York, Usa Illus 529-533, 1989

Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. Journal of Applied Physiology 71(3): 807-814, 1991

Myocardiopathy and expression of atrial natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. Journal of Veterinary Medical Science 56(4): 651-655, 1994

Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. American Review of Respiratory Disease 136(4): 951-956, 1987

The determination of pulmonary artery hypertension by levels of plasma atrial natriuretic peptide and pulmonary perfusion imaging. Journal of China Medical University 30(1): 61-63, 2001

Role of endogenous atrial natriuretic peptide in sodium excretion in rats with experimental pulmonary hypertension. Japanese Circulation Journal 55(SUPPL A): 318-319, 1991